Wayne Hummer Investments L.L.C. Has $758,000 Position in Bristol-Myers Squibb Company (BMY)

Wayne Hummer Investments L.L.C. lifted its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 16.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,611 shares of the biopharmaceutical company’s stock after buying an additional 1,875 shares during the quarter. Wayne Hummer Investments L.L.C.’s holdings in Bristol-Myers Squibb were worth $758,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Tradewinds Capital Management LLC raised its holdings in shares of Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares during the period. Welch Investments LLC increased its holdings in Bristol-Myers Squibb by 3.9% during the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 79 shares during the last quarter. Blue Chip Partners Inc. increased its holdings in Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 17 shares during the last quarter. American National Bank increased its holdings in Bristol-Myers Squibb by 11.7% during the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 225 shares during the last quarter. Finally, Proficio Capital Partners LLC increased its holdings in Bristol-Myers Squibb by 29.6% during the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 504 shares during the last quarter. Institutional investors and hedge funds own 68.93% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/11/03/wayne-hummer-investments-l-l-c-has-758000-position-in-bristol-myers-squibb-company-bmy.html.

Several equities research analysts have issued reports on the company. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday. SunTrust Banks, Inc. upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday. Credit Suisse Group restated a “hold” rating and set a $61.00 price objective (up from $58.00) on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Piper Jaffray Companies restated a “hold” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Finally, BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $64.93.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same period in the previous year, the company posted $0.77 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis.

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.51%. Bristol-Myers Squibb’s payout ratio is presently 61.42%.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit